[Tiotropium bromide (Spiriva) in stablechronic obstructive pulmonary disease].
The present review of literature, dedicated to the usage of anticholinergic drug Tiotropium Bromide (Spiriva) in the treatment of stable chronic obstructive pulmonary disease (COPD), demonstrates its supremacy over Ipratropium Bromide (Atrovent) and sympathomimetics in relation to broncholytic effect as well as in the capacity to improve the clinical symptoms of the disease, the quality of life for the patients, prevent the exacerbations, reduce the frequency of hospitalization of the diseased in the stationer and raise the physical capacity of work. It is also important that due to its antycholinergic activity during 48 hours and of high 24-hour continuous action it is possible to prescribe Spiriva once in 24 hours. Such qualities of a drug greatly simplify regime of the dosage and improve the compliance of the patients towards the therapy. The present review gives us the possibility to discuss the effectiveness of the Tiotropium Bromide (Spiriva) as well as of its safety that puts this medicine above all other drugs used in the treatment of COPD.
Lobzhanidze
T V
TV
Sikharulidze
L P
LP
Kurdegeliia
M R
MR
D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D000069447:Tiotropium Bromide
D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D000069447:Tiotropium Bromide